ZL006

ZL006 is a **small molecule inhibitor** designed to disrupt the interaction between postsynaptic density protein 95 kDa (PSD-95) and neuronal nitric oxide synthase (nNOS) at the N-methyl-D-aspartate receptor (NMDA-R) complex[1]. By blocking this protein-protein interaction, ZL006 indirectly inhibits NMDA receptor-mediated nitric oxide production without directly antagonizing NMDA receptors or inhibiting nNOS enzymatic activity[1]. This approach aims to reduce nitric oxide (NO)-mediated neurotoxicity, particularly in diseases like ischemic stroke and depression[1][2]. ZL006 has shown efficacy in preclinical models for **ischemic stroke** and has been investigated as a potential treatment for depression, but it does not elicit robust antidepressant-like behavioral effects in standard animal paradigms with acute dosing[1][3]. Mechanistically, ZL006 reduces total nitrate/nitrite concentrations in brain tissue, a marker for nitric oxide metabolites[1].

Brand names

ZL006ZL-006ZL 006

Other names

ZL006ZL-006ZL 006